UNG THƯ PHỔI TẾ BÀO NHỎ (SCLC) - BÁO CÁO CA BỆNH VÀ TỔNG QUAN TÀI LIỆU

Abstract

Small cell lung cancer (SCLC) is a dangerous disease, accounting for about 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed with SCLC each year. Overall 5-year survival remains low at <7%, and most patients live 1 year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which great advances have been made using targeted therapies, there is no approved targeted drug for SCLC to date. Significant barriers to progress in SCLC include: (1) lack of early detection modalities; (2) limited tumor tissue for study of translation (molecular profiles of DNA, RNA, and/or protein alterations) because diagnostic biopsy specimens are often small and surgical resection is rare in the treatment; (3) rapidly progressive disease with little understanding of the mechanisms of resistance to treatment. We report a case of SCLC diagnosed and treated at the National Lung Hospital. The discussion section looks at the current state of SCLC diagnosis and treatment, addresses recent advances in understanding the underlying disease biology, and opportunities to improve treatments for patients with SCLC.